

November 6, 2018



NewBridge Global Ventures Subsidiary, The Bay Clonery Project, Developing Industrial Scale Tissue Culture Production Process for Cannabis

Alameda, California, Nov. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- NewBridge Global Ventures, Inc. ("NewBridge" or the "Company"), (OTCQB: NBGV), a company focused on the emerging and dynamic legal and regulated cannabis industry, today announced that its subsidiary, The Bay Clonery LLC, is developing an industrial scale tissue culture production process for cannabis that is expected to be operational during the first quarter of 2019.

In agriculture, tissue culture has been around for years to rid plants of disease and ensure consistency, however it's relatively new to the cannabis and industrial hemp industry. The Bay Clonery Project has developed an industrial scale tissue culture production process for cannabis, with standardizations for plants grown in accordance with a set of practices (SOP's), which frees them of pathogens and pesticides and saves farmers wasted money caused by diseased plants.

The Bay Clonery is building out a 5,000 square foot warehouse at Company owned facilities inside a 45,000 square foot compound in Santa Rosa California, that also has 16 clean rooms totaling over 15,000 square feet for housing clones when permitted.

The proven advantages of producing clean and disease-free plants from tissue culture, The Bay Clonery Tissue Culture Lab will cultivate mature plants with chosen and desirable characteristics such as THC and CBD content, terpene profiles, and other strain specific traits. Tissue culture creates the possibility for product uniformity and standardization within the cannabis industry.

The Bay Clonery Tissue Culture Lab is committed to preserving desirable genetics and proprietary cannabis and hemp strains by collaborating with breeders and seed banks to archive a library which will not only allow the purpose of testing and cross-breeding but also isolating compounds that can and should be used as medicine. Overall, tissue culture science will optimize production capability, preserve genetics and reduce the pathogen risks associate with traditional cannabis operations.

Bob Bench, Interim President of NewBridge, commented, "By focusing on the nursery part of the supply chain - curating and helping create new genetics and mass-producing those genetics - The Bay Clonery Project helps Growers feel more confident about the quality of

the plants they receive and be more efficient in their production. By using genomics and breeding as a tool, we deliver varieties that have higher disease resistance, better agronomic traits and create higher yields. In doing so, we help increase a Grower's profit, reduce its risk, and create new products. Overall, The Bay Clonery Project helps a Grower strengthen and expand its cultivation operations and is illustrative of the quality of NewBridge Global Ventures' fully integrated vertical cannabis platform.”

About NewBridge Global Ventures

NewBridge Global Ventures, Inc. (OTCQB: NBGV) is a US public company acquiring and currently operating a vertically integrated portfolio of California cannabis and hemp companies. Our vertical structure includes: genetics, cloning, cultivation, manufacturing, distribution, consulting services to industry entrepreneurs, and education for medical professionals. We believe by focusing on compliance, industry best practices, standardization, and corporate governance NewBridge Global Ventures, Inc. will be squarely positioned for rapid sales growth in the legal California cannabis and industrial hemp Industry. For more information go to: www.newbridgegv.com

Forward-Looking Statements

Statements about the expected timing, and all other statements in this press release, other than historical facts, constitute forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date hereof and are based on current expectation and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those projected. A number of the matters discussed herein that are not historical or current facts deal with potential future circumstances and developments that may or may not materialize. This press release speaks only as of its date, and except as required by law, we disclaim any duty to update.

Contacts:

Bob Bench, Interim President

bob@newbridgegv.com

801-362-2115

Investors:

Stephanie Prince

PCG Advisory Group

sprince@pcgadvisory.com

646.762.4518

Source: NewBridge Global Ventures, Inc.